ACE2 and infection: Here, we report that soluble ACE2 (APN01), already being tested in clinical trials (NCT04335136), binds receptor‐binding domain (RBD) and full‐length Spike proteins of SARS‐CoV‐2 variants and especially VOCs with increased affinity when compared to the SARS‐CoV‐2 reference strain Spike and effectively neutralizes infections of all tested variants.